Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other

PharmAla To Supply Amsterdam UMC with LaNeo(TM) MDMA, Including Development of New Single-Capsule Stability Data

By The Northwire Desk — AI Analysis Feb 23, 2026 · 08:30 MDMA · 0.1 Pharmala Biotech Holdings Inc.
MDMA · Price

Executive Summary

  • PharmAla Biotech Holdings Inc. has executed a binding supply agreement with Amsterdam University Medical Center (Amsterdam UMC) to provide LaNeo™ 40 mg MDMD capsules for a proposed clinical trial.
  • The contract includes a three‑year stability‑testing program for the single‑capsule dosage form, data that will be used to develop commercial‑grade blister packaging—critical for future commercialization.
  • Delivery is contingent on a Quality Agreement and customary regulatory approvals; the agreement expands PharmAla’s European clinical footprint and supports its broader commercial strategy.

Key Details

  • Parties: PharmAla Biotech Holdings Inc. (CSE: MDMA / OTCQB: MDXXF) and Amsterdam University Medical Center, Netherlands.
  • Product Supplied: LaNeo™ 40 mg MDMA capsules, repackaged in a new single‑capsule format.
  • Stability Program: Three‑year testing of the single‑capsule dosage to generate stability data for future blister packaging development.
  • Commercial Implication: Stability data is a prerequisite for commercial‑grade blister packs, the industry standard for pharmaceutical distribution, enabling more efficient global trial and commercial supply.
  • Conditional Elements: Execution of a Quality Agreement with Amsterdam UMC’s Clinical Pharmacy; delivery subject to regulatory approvals and direction from Amsterdam UMC.
  • Strategic Impact: Enhances PharmAla’s European value chain, supports researchers across the continent, and moves the company toward a “truly commercial‑grade product.”

Notable Quotes

“We are delighted to be working with Amsterdam UMC, one of Europe’s leading academic medical centres… the stability testing program … will generate single‑capsule stability data that we intend to use as the foundation for developing blister packaging for LaNeo™ MDMA. This is an important step towards a truly commercial‑grade product.” – Nicholas Kadysh, CEO, PharmAla Biotech Holdings Inc.

Read the original news release →

More from Pharmala Biotech Holdings Inc.

May 20, 2026 · 08:15

PharmAla’s ALA-002 draws a nine-figure pact with Nasdaq-listed Jupiter, signalling Big Pharma-style validation for next-gen MDMA in a transformed U.S. regulatory landscape.

Other May 20, 2026 · 07:38

PharmAla’s $100M-Plus ALA-002 Licensing Pact with Nasdaq’s Jupiter Validates Next-Gen MDMA, Fueling a Pivotal Re-Rating

M&A / Property May 13, 2026 · 08:30

PharmAla Advances APA-01 SPV Deal; Royalty Stream Contingent on Funding

M&A / Property Apr 27, 2026 · 08:00

PharmAla Biotech Monetizes APA-01 IP via SPV Amidst Psychedelic Regulatory Tailwinds

Other Apr 21, 2026 · 16:05

PharmAla Biotech Gains on Regulatory Tailwinds as Earnings Confirm Growth Amidst Management Shake-Up

Earnings Apr 20, 2026 · 08:15

CSE: MDMA

Production / Operations